Utilidad de Modafilino en trastorno por déficit de atención en hiperactividad
Descargas
Publicado
2007-12-01
Cómo citar
de Sande Díaz, F., León Quintana, C., Martín Recuero, L., & Gutiérrez Casares, J. R. (2007). Utilidad de Modafilino en trastorno por déficit de atención en hiperactividad. Revista De Psiquiatría Infanto-Juvenil, 24(2, 3 y 4), 193–199. Recuperado a partir de https://aepnya.eu/index.php/revistaaepnya/article/view/101
Número
Sección
Artículo original
Palabras clave:
TDAHResumen
El trastorno por déficit de atención e hiperactividad (TDAH) afecta a un importante rango de población infantil y adolescentes. Modafinilo es una molécula rempleada y aprobada para el tratamiento de la narcolepsia y otros trastornos del sueño. Se han realizado diversos ensayos clínicos en lo que se midió mediante escalas la efectividad de este fármaco para el TDAH tanto en niños y adolescentes como en adultos. Por el momento los ensayos han obtenido resultados positivos tanto en a efectividad como en la tolerabilidad y potencial de abuso del fármaco. Los efectos adversos más comunes fueron cefaleas, insomnio y pérdida de apetito. Se necesitan nuevos ensayos clínicos que midan la efectividad de modafinilo en TDAH comparada con la de los fármacos estimulantes utilizados en esta patología.
Descargas
Los datos de descargas todavía no están disponibles.
Citas
1. American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000;105:1158-1170.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th ed.Washington, DC:American Psychiatric Press. 1994.
3. Scammell TE, Estabrooke IV, McCarthy MT, Chemelli RM, Yanagisawa M, Miller MS, et al : Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci. 2000:20:8620 -8628.
4. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K: Modafinil: An antinarcoleptic drug with a different neurochemical pro- file to d-amphetamine and dopamine uptake blockers. Biol Psychiatry. 1997:42:1181-1183.
5. Ferraro L, Tanganelli S, O'Connor WT, Antonelli T, Rambert F, Fuxe K:The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: Possible involvement of the serotonergic 5-HT3 receptor. Neurosci Lett. 1996:220:5-8.
6. Akaoka H, Roussel B, Lin JS, Chouvet G, Jouvet M: Effect of modafinilo and amphetamine on the rat catecholaminergic neuron activity. Neurosci Lett. 1991:123:20 -22.
7. Lin JS, Roussel B,Akaoka H, Fort P, Debilly G, JouvetM: Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res. 1992;591:319-326.
8. Simon P, Panissaud C, Costentin J, The stimulant effect of modafinil on wakefulness is not associated with an increase in anxiety in rats.Acomparison with dexamphetamine. Psychopharmacology 1990:114 (4):597-600.
9. Mignot E, Nishino S, Guilleminault C, DementWC: Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep. 1994:17:436 - 437.
10. Cephalon UK Limited Provigil Product Monograph. PRO517/Dec2002
11. Ferraro L, Fuxe K, Agnati L, Tanganelli S, Tomasini MC, Antonelli T.Modafinil enhances the increase of extracellular serotonin levels induced by the antidepressant drugs fluoxetine and imipramine: a dual probe microdialysis study in awake rat. Synapse. 2005 Mar 15;55(4):230-41.
12. Wong YN, King SP, Laughton WB, McCormick GC, Grebow. Singledose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers. J Clin Pharmacol. 1998:38:276-282.
13. Wong YN, King SP, Simcoe D, Gorman S, Laughton W, McCormick GC, Grebow P Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin
Pharmacol 1999 Mar; 39(3):281-8
14. Robert C. Bransfield,MD Potential Uses of Modafinil in Psychiatric Disorders. The Journal of Applied Research. 2004:Vol. 4, No. 2,
15. DeBattista C, Lembke A, Solvason HB, Ghebremichael R, Poirier J. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol. Feb 2004;24(1):87-90.
16. Lundt L. Modafinil treatment in patients with seasonal affective disorder/winter depression: an open-label pilot study. J Affect Disord. Aug 2004;81(2):173-178.
17. Rosenthal MH, Bryant SL. Benefits of adjunct modafinil in an openlabel, pilot study in patients with schizophrenia. Clin Neuropharmacol. Jan-Feb 2004;27(1):38-43.
18. Saletu B, Saletu M, Grunberger J, Frey R, Anderer P, Mader R. Treatment of the alcoholic organic brain syndrome: double-blind, placebo-controlled clinical, psychometric and electroencephalographic mapping studies with modafinil. Neuropsychobiology. 1993;27(1):26-39.
19. Saletu B, Saletu M, Grunberger J, Frey R, Zatschek I, Mader R. On the treatment of the alcoholic organic brain syndrome with an alpha-adrenergic agonist modafinil: double-blind, placebo-controlled clinical, psychometric and neurophysiological studies. Prog Neuropsy-chopharmacol Biol Psychiatry. 1990;14(2):195-214.
20. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry. Feb 2002;72(2):179-183.
21. Nieves AV, Lang AE. Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin Neuropharmacol. Mar-Apr 2002;25(2):111-114.
22. Hogl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. Dec15 2002;25(8):905-909.
23. Damian MS, Gerlach A, Schmidt F, Lehmann E, Reichmann H. Modafinil for excessive daytime sleepiness in myotonic dystrophy. Neurology. Mar 27 2001;56(6):794-796.
24. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP Neuropsychopharmacology. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology. 2005 Jan;30(1):205-11.
25. Rugino TA, Samsock TC. Modafinil in children with attention-deficit hyperactivity disorder. Pediatric Neurology. 2003;29(2):136-142.
26. Rugino TA, Copley TC. Effects of modafinilo in children with attention- 199 deficit/hyperactivity disorder: an open-label study. J Am Acad Child Adolesc Psychiatry. 2001;40:230-235.
27. Greenhill LL, Biederman J, Boellner SW, Rugino TA, Sangal RB, Earl CQ, Jiang JG,Swanson JM. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006 May;45(5):503-11.
28. Swanson JM, Greenhill LL, Lopez FA, Sedillo A, Earl CQ, Jiang JG, Biederman J.Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry. 2006 Jan;67(1):137-47.
29. Biederman J, Swanson JM,Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ, Jiang J,Greenhill L.Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention deficit/hyperactivity disorder: results of a randomized,double-blind, placebo-controlled, flexible dose study. Pediatrics. 2005 Dec;116(6):e777-84.
30. Biederman J, Swanson JM,Wigal SB, Boellner SW, Earl CQ, Lopez FA; Modafinil ADHD Study Group. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study. J Clin Psychiatry. 2006 May;67(5):727-35.
31. Swanson JM, Biederman J, Boelder SW, Earl C, Lopez FA. Modafinil as a therapy forADHD in children: an 8-week , open trial study. J. Child Adolesc. Psychopharmacol. 14(4),512-512 (2004).
32. Swanson JM, Greenhill LL, Biederman J. Modafinil in children with ADHD; a randomized, placebo-controlled study. Annual Meeting of The American Psychiatry Association. San Francisco, CA, USA May 17-22 2003. Syllabus and scientific proceedings in summary form Abstract no. 44(2003).
33. Doctor´s Guide. No benefit noted from Provigil (modafinil) in adult attention deficit and hyperactivity disorder. New Release 31 July 2000, www.psigroup.com/dg/1db532.htm (2000).
34. Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. Journal of Child & Adolescent Psychopharmacology. 2000;10(4):311-320.
35. Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ. Modafinil improves cognition and response inhibition in adult attention deficit/hyperactivity disorder. Biological Psychiatry. 2004;55 (10):1031-1040.
36. Narendran R, Young CM, Valenti AM, Nickolova MK, Pristach CA. Is psychosis exacerbated by modafinil?. Arch Gen Psychiatry.2002 Mar;59(3):292-3.
37. Mariani JJ, Hart CL. Psychosis associated with modafinil and shift work. Am J Psychiatry. 2005 Oct;162(10):1983.
38. Jasinski DR: An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol. 2000:14:53-60.
39. Myrick H, Malcolm R, Taylor B, LaRowe S. Modafinil: preclinical, clinical, and post-marketing surveillance-a review of abuse liability issues. Ann Clin Psychiatry. 2004;16:101-109.
40. Turner D.A review of the use of modafinil for attention-deficit hyperactivity disorder. Expert Rev Neurother. 2006 Apr;6(4):455-68.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th ed.Washington, DC:American Psychiatric Press. 1994.
3. Scammell TE, Estabrooke IV, McCarthy MT, Chemelli RM, Yanagisawa M, Miller MS, et al : Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci. 2000:20:8620 -8628.
4. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K: Modafinil: An antinarcoleptic drug with a different neurochemical pro- file to d-amphetamine and dopamine uptake blockers. Biol Psychiatry. 1997:42:1181-1183.
5. Ferraro L, Tanganelli S, O'Connor WT, Antonelli T, Rambert F, Fuxe K:The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: Possible involvement of the serotonergic 5-HT3 receptor. Neurosci Lett. 1996:220:5-8.
6. Akaoka H, Roussel B, Lin JS, Chouvet G, Jouvet M: Effect of modafinilo and amphetamine on the rat catecholaminergic neuron activity. Neurosci Lett. 1991:123:20 -22.
7. Lin JS, Roussel B,Akaoka H, Fort P, Debilly G, JouvetM: Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res. 1992;591:319-326.
8. Simon P, Panissaud C, Costentin J, The stimulant effect of modafinil on wakefulness is not associated with an increase in anxiety in rats.Acomparison with dexamphetamine. Psychopharmacology 1990:114 (4):597-600.
9. Mignot E, Nishino S, Guilleminault C, DementWC: Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep. 1994:17:436 - 437.
10. Cephalon UK Limited Provigil Product Monograph. PRO517/Dec2002
11. Ferraro L, Fuxe K, Agnati L, Tanganelli S, Tomasini MC, Antonelli T.Modafinil enhances the increase of extracellular serotonin levels induced by the antidepressant drugs fluoxetine and imipramine: a dual probe microdialysis study in awake rat. Synapse. 2005 Mar 15;55(4):230-41.
12. Wong YN, King SP, Laughton WB, McCormick GC, Grebow. Singledose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers. J Clin Pharmacol. 1998:38:276-282.
13. Wong YN, King SP, Simcoe D, Gorman S, Laughton W, McCormick GC, Grebow P Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin
Pharmacol 1999 Mar; 39(3):281-8
14. Robert C. Bransfield,MD Potential Uses of Modafinil in Psychiatric Disorders. The Journal of Applied Research. 2004:Vol. 4, No. 2,
15. DeBattista C, Lembke A, Solvason HB, Ghebremichael R, Poirier J. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol. Feb 2004;24(1):87-90.
16. Lundt L. Modafinil treatment in patients with seasonal affective disorder/winter depression: an open-label pilot study. J Affect Disord. Aug 2004;81(2):173-178.
17. Rosenthal MH, Bryant SL. Benefits of adjunct modafinil in an openlabel, pilot study in patients with schizophrenia. Clin Neuropharmacol. Jan-Feb 2004;27(1):38-43.
18. Saletu B, Saletu M, Grunberger J, Frey R, Anderer P, Mader R. Treatment of the alcoholic organic brain syndrome: double-blind, placebo-controlled clinical, psychometric and electroencephalographic mapping studies with modafinil. Neuropsychobiology. 1993;27(1):26-39.
19. Saletu B, Saletu M, Grunberger J, Frey R, Zatschek I, Mader R. On the treatment of the alcoholic organic brain syndrome with an alpha-adrenergic agonist modafinil: double-blind, placebo-controlled clinical, psychometric and neurophysiological studies. Prog Neuropsy-chopharmacol Biol Psychiatry. 1990;14(2):195-214.
20. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry. Feb 2002;72(2):179-183.
21. Nieves AV, Lang AE. Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin Neuropharmacol. Mar-Apr 2002;25(2):111-114.
22. Hogl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. Dec15 2002;25(8):905-909.
23. Damian MS, Gerlach A, Schmidt F, Lehmann E, Reichmann H. Modafinil for excessive daytime sleepiness in myotonic dystrophy. Neurology. Mar 27 2001;56(6):794-796.
24. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP Neuropsychopharmacology. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology. 2005 Jan;30(1):205-11.
25. Rugino TA, Samsock TC. Modafinil in children with attention-deficit hyperactivity disorder. Pediatric Neurology. 2003;29(2):136-142.
26. Rugino TA, Copley TC. Effects of modafinilo in children with attention- 199 deficit/hyperactivity disorder: an open-label study. J Am Acad Child Adolesc Psychiatry. 2001;40:230-235.
27. Greenhill LL, Biederman J, Boellner SW, Rugino TA, Sangal RB, Earl CQ, Jiang JG,Swanson JM. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006 May;45(5):503-11.
28. Swanson JM, Greenhill LL, Lopez FA, Sedillo A, Earl CQ, Jiang JG, Biederman J.Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry. 2006 Jan;67(1):137-47.
29. Biederman J, Swanson JM,Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ, Jiang J,Greenhill L.Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention deficit/hyperactivity disorder: results of a randomized,double-blind, placebo-controlled, flexible dose study. Pediatrics. 2005 Dec;116(6):e777-84.
30. Biederman J, Swanson JM,Wigal SB, Boellner SW, Earl CQ, Lopez FA; Modafinil ADHD Study Group. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study. J Clin Psychiatry. 2006 May;67(5):727-35.
31. Swanson JM, Biederman J, Boelder SW, Earl C, Lopez FA. Modafinil as a therapy forADHD in children: an 8-week , open trial study. J. Child Adolesc. Psychopharmacol. 14(4),512-512 (2004).
32. Swanson JM, Greenhill LL, Biederman J. Modafinil in children with ADHD; a randomized, placebo-controlled study. Annual Meeting of The American Psychiatry Association. San Francisco, CA, USA May 17-22 2003. Syllabus and scientific proceedings in summary form Abstract no. 44(2003).
33. Doctor´s Guide. No benefit noted from Provigil (modafinil) in adult attention deficit and hyperactivity disorder. New Release 31 July 2000, www.psigroup.com/dg/1db532.htm (2000).
34. Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. Journal of Child & Adolescent Psychopharmacology. 2000;10(4):311-320.
35. Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ. Modafinil improves cognition and response inhibition in adult attention deficit/hyperactivity disorder. Biological Psychiatry. 2004;55 (10):1031-1040.
36. Narendran R, Young CM, Valenti AM, Nickolova MK, Pristach CA. Is psychosis exacerbated by modafinil?. Arch Gen Psychiatry.2002 Mar;59(3):292-3.
37. Mariani JJ, Hart CL. Psychosis associated with modafinil and shift work. Am J Psychiatry. 2005 Oct;162(10):1983.
38. Jasinski DR: An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol. 2000:14:53-60.
39. Myrick H, Malcolm R, Taylor B, LaRowe S. Modafinil: preclinical, clinical, and post-marketing surveillance-a review of abuse liability issues. Ann Clin Psychiatry. 2004;16:101-109.
40. Turner D.A review of the use of modafinil for attention-deficit hyperactivity disorder. Expert Rev Neurother. 2006 Apr;6(4):455-68.
© 2021 AEPNyA Todos los derechos reservados
